Faisal Khurshid
Stock Analyst at Leerink Partners
(0)
# 4361
Out of 5,329 analysts
20
Total ratings
23.08%
Success rate
-13.00%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
IRWD Ironwood Pharmaceuti... | Maintains: Market Perform | 3 1 | 0.93 | 7.53% | 2 | Apr 14, 2025 | |
SYRE Spyre Therapeutics | Initiates Coverage On: Outperform | 45 | 14.68 | 206.54% | 1 | Apr 8, 2025 | |
NRIX Nurix Therapeutics | Initiates Coverage On: Market Perform | 16 | 11.2 | 42.86% | 1 | Mar 17, 2025 | |
STTK Shattuck Labs | Initiates Coverage On: Outperform | 4 | 1.08 | 270.37% | 1 | Mar 17, 2025 | |
PLRX Pliant Therapeutics | Downgrades: Market Perform | 33 2 | 1.61 | 24.22% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 16 | 3.35 | 377.61% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 60 60 | 34.63 | 73.26% | 2 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 80 | 70.81 | 12.98% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 15 | 1.47 | 920.41% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 7 | 6.92 | 1.16% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 45 | 17.66 | 154.81% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 24 | 26.79 | -10.41% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 7 | 1.42 | 392.96% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 8 | 4.96 | 61.29% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 5 | 1.17 | 327.35% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 17 21 | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 11 | 4.58 | 140.17% | 1 | Mar 21, 2023 |